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Abstract
Introduction: The primary objectives were to explore the associations between a comprehensive ultrasonographic
(US) assessment of joints, tendons and bursae and previously described reduced joint counts (7-, 12-, 28- and 44-
joint score) as well as to assess the sensitivity to change of these different US joint combinations during biological
treatment.
Methods: Twenty patients with rheumatoid arthritis (RA) were examined by US (B-mode (BM) and power Doppler
(PD)) with use of a semi-quantitative (0 to 3) score of 78 joints, 36 tendons/tendon groups and two bursae
(hereafter described as the 78-joint score) at baseline and 1, 3, 6 and 12 months after initiating treatment with
adalimumab. BM and PD scores for the different joint combinations were generated.
Results: The reduced joint scores had high correlation coefficients with the 78-joint score at all examinations
(range 0.79 to 0.99 for BM and 0.77 to 0.99 for PD, each P < 0.001) and sum BM and PD scores of all the different
joint combinations improved significantly during follow-up (P ≤ 0.05 to 0.001).
Conclusions: The reduced joint combinations were highly associated to the 78-joint score. Furthermore, all the
joint combinations presently explored responded well to biological treatment. This indicates that an approach
focusing on few joints and tendons gives equivalent information about the inflammatory activity in RA patients as
a comprehensive US examination. The optimal combination of joints and tendons for a valid, reliable and feasible
US measurement should be further explored to define a US score for follow-up of RA patients on biological
treatment.
Introduction
Ultrasonography (US) is increasingly used for evaluation
of synovitis in patients with inflammatory joint diseases,
and synovitis and effusion are detected by grey scale (B-
mode, BM) and vascularization by use of power Doppler
(PD) [1]. US is a validated and reliable method for asses-
sing joint inflammation [2-5] and it is sensitive to
change during treatment with biological medication
[5-8]. Different joint combinations have been proposed
for optimal and/or feasible assessments of joint inflam-
mation in patients with rheumatoid arthritis (RA). The
7-joint score by Backhaus et al. [9] was evaluated in a
longitudinal multicenter German study and found to
reflect disease activity and therapeutic response. Naredo
et al. [10] developed from a 44-joint score in a multi-
center Spanish study a 12-joint score that was useful in
monitoring the response to biological medications.
Another 44-joint score was used by Scirè et al. [11] and
a 28-joint US score assessing the joints included in the
composite DAS28 score [12] has been used in longitudi-
nal and cross-sectional studies [3,5,13]. We have
recently shown that US assessment of 78 joints also was
sensitive to change during adalimumab treatment [14].
Thus, several joint combinations have been demon-
strated to be useful in the assessment of RA patients,
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but further work is needed to identify the optimal com-
binations of joints for therapeutic assessment. In addi-
tion, tenosynovitis is a frequent pathology in RA
patients and both US and MRI assessments have been
shown to be responsive [15,16] and thus evaluation of
tenosynovitis may be considered for inclusion in an
optimal US score.
The objectives of the present longitudinal study of RA
patients were to assess the associations between a com-
prehensive US score (including 78 joints, 36 tendons
and 2 bursae) and existing reduced scores of 7-, 12-, 28-
and 44-joints and to explore the responsiveness of the
various joint scores during biological treatment.
Materials and methods
A comprehensive US assessment of joints, tendons and
bursae was performed in 20 patients with RA [17] (med-
ian (range) age 53 (21 to 78) years, disease duration 7.5
(1 to 26) years, 15 women, 70% IgM rheumatoid factor
positive). US assessments of the 78 joints in these
patients were previously described [14] as well as the
wrist- and ankle tendon assessments [15]. In addition,
the patients were examined bilaterally for tenosynovitis
in the long biceps tendon and for inflammation in sub-
deltoid bursa. The patients were consecutively included
the same day as they started treatment with adalimumab
(40 mg every other week) as their first biological medi-
cation. All patients also received methotrexate and 14
patients used additionally prednisolone (median range
dose: 7.5 (3.75 to 15) mg per day). US examinations
were performed by one experienced sonographer (HBH)
at baseline and after 1, 3, 6 and 12 months with use of a
5 to 13 MHz probe (Siemens Antares, Sonoline, Sie-
mens Medical Solutions, 1230 Shorebird Way Mountain
View, CA, USA) and fixed settings (PD with frequency
7.3 MHz and pulse repetitive frequency 391 Hz) [18].
The same machine and setting (without upgrading) was
used throughout the study. The following joints were
assessed bilaterally by use of standard longitudinal pro-
jections (scanning positions in parenthesis) [19]: proxi-
mal interphalangeal (PIP) 1 to 5 (dorsal),
metacarpophalangeal (MCP) 1 to 5 (dorsal), carpometa-
carpal (CMC) 1 to 5 (CMC 1 radial/palmar, CMC 2 to
5 dorsal), wrist (each of the radiocarpal, intercarpal and
radioulnar joints) (dorsal), elbow (anterior, lateral and
posterior), shoulder (glenohumeral, with scanning dorsal
transverse with maximal external rotation of the arm
and acromioclavicular joints with longitudinal scanning),
hip (anterior), knee (suprapatellar and lateral), ankle
(talocrural joint) (anterior), four major foot joints (talo-
navicular, calcaneocuboidal, cuneonavicular, subtalar)
(anterior and lateral), tarsometatarsal 1 to 5 (dorsal),
metatarsophalangeal (MTP) 1 to 5 (dorsal) and the
interphalangeal (dorsal) joint of the first toe (a total of
78 joints) [14]. In addition, tendons were examined
bilaterally by use of definitions as described by OMER-
ACT [1]. The extensor tendons of the wrists were
assessed at the level of the radiocarpal joint and the
examination included tendons of all six compartments:
abductor pollicis longus and extensor pollicis brevis;
extensor carpi radialis brevis and longus; extensor polli-
cis longus; extensor digitorum and extensor indicis;
extensor digiti minimi; extensor carpi ulnaris. At the
palmar side, three flexor tendons/groups were examined
bilaterally at the level of the radiocarpal joint; flexor pol-
licis longus, flexor carpi radialis and combined flexor
digitorum superficialis and profundus. In the ankles,
eight tendons were assessed bilaterally: peroneus longus
and brevis (behind the lateral malleol), extensor digi-
torum longus, extensor hallucis longus and tibialis ante-
rior (anterior at the level of the distal tibia), tibialis
posterior, flexor digitorum longus and flexor hallucis
longus (behind the medial malleol) [15]. The long biceps
tendon (anterior) was also examined, and thus a total of
36 tendons/tendon groups were evaluated. All tendons
were assessed transversely by moving the probe proxi-
mally and then distally along the tendons and finally
longitudinally by moving the probe medially and later-
ally over the tendon/tendon groups. In addition, poten-
tial abnormalities in subdeltoid bursa were explored
bilaterally by use of a transverse scan at the level of
tuberculum major, and the size and PD activity were
evaluated using additionally scans, as required. The
joints, tendons and bursae were scored for BM (pre-
sence of synovitis and joint fluid) and PD (presence of
vascularization) as score 0 = none, score 1 = minor,
score 2 = moderate or score 3 = major presence.
All US examinations were performed in one room in
the morning, after at least half an hour of acclimatiza-
tion to room temperature [20]. The pressure of the
probe was as low as possible to obtain optimal PD sig-
nals. The hands and fingers were assessed while resting
on a small table, the elbows were examined in extension
and flexion, the shoulders with the patient sitting and
the lower limbs were examined with the patient lying on
a bench. The US examiner was blinded for previous US
results as well as for the results from clinical and labora-
tory examinations the same day.
Reliability tests for US scoring of joints were per-
formed on acquired images with median (range)
intraobserver intraclass correlation coefficients (95% CI)
of 0.97 (0.96 to 0.98) for BM scores and 0.98 (0.97 to
0.99) for PD scores [14]. No reliability tests were, how-
ever, performed for the scoring of tendons and bursae.
With the BM or PD scores from the comprehensive
assessment of 78 joints, 36 tendons or tendon groups
and 2 bursae (hereafter called the 78-joint score) as
basis, sum scores of BM or PD for the different joint
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combinations/joint scores were computed. The 7-joint
score by Backhaus et al. includes examination of the
wrist, MCP 2 and 3, PIP 2 and 3, and MTP 2 and 5 at
the clinically dominant side with assessment of synovitis,
paratenonitis/tenosynovitis and erosions [9]. However,
neither examination of flexor tenosynovitis in the sec-
ond and third finger nor assessments of erosions were
performed in this study, and joints and tendons on the
patients right side were presently defined as being the
dominant side and included in the calculations of the 7-
joint score. The original 7-joint score includes assess-
ment of BM synovitis in MCP 2 and 3 only from the
palmar view, paratenonitis/tenosynovitis from both dor-
sal and palmar aspect, and PD assessments on both pal-
mar and dorsal aspect of these joints. The PIP two and
three joints were in the 7-joint score assessed for syno-
vitis only on the palmar aspect while PD assessments
were performed both at dorsal and palmar side. In our
study only dorsal scans were performed on MCP and
PIP joints and thus these scores were included in the
present calculations. The wrist was in the 78-joint score
examined as the radiocarpal, intercarpal and radioulnar
joints separately, and the sum of these scores was
included as the wrist-assessment in the 7-joint score.
The tendons described as dorsal and ulnar part of the
wrist in the 7-joint score were in this study defined as
compartment 4 and 6 of the extensor tendons, and the
palmar tendons were defined as the superficial and deep
flexor tendons, and they were all included in the sum 7-
joint score.
The 12-joint score by Naredo et al. [10] includes bilat-
eral examination of the elbow, wrist, MCP 2 and 3, knee
and ankle in addition to the medial and lateral tendon
compartments in the ankle. In the original 12-joint
score the wrist was described as the dorsal carpal recess,
which was presently defined as the radiocarpal and
intercarpal joints. Except for both palmar and dorsal
evaluation of MCP 2 and 3 joints in the 12-joint score,
the scannings of joints and tendons were similar to the
78-joint score.
The 28-joint score [5,13] includes the same 28 joints
as used in the DAS28 score [12] with bilateral examina-
tion of the glenohumeral joint, elbow, wrist, MCP 1 to
5, PIP 1 to 5 and knee with similar scanning method as
used in the 78-joint score. However, since the wrist
score was not clearly defined, the highest score of the
radiocarpal, intercarpal and radioulnar joints was used
in this study for the calculation of sum scores for BM
and PD of these 28 joints.
The 44-joint score by Naredo et al. [10] includes the
glenohumeral joint, elbow, wrist, MCP 1 to 5, PIP 1 to
5, hip, knee, ankle, midtarsal joints and MTP 1 to 5
joints. From the 78-joint score we used the highest
score of the three wrist joints and the highest score of
the midtarsal joints for the calculations of the 44-joint
score. In addition, the 44-joint score includes the biceps,
dorsal and palmar wrist tendons, medial, anterior and
lateral ankle tendons as well as the subdeltoid bursae.
Thus all these tendons and bursae were included in the
present calculations. Table 1 displays an overview of the
joints, tendons and bursae included in the different
reduced joint scores.
The patients gave written consent according to the
Declaration of Helsinki, and the study was approved by
the local ethics committee (the regional committee for
medical and health research ethics (REK), South-East).
Statistics
Wilcoxon signed rank test was used to examine changes
in US sum scores during follow-up for the different
joint combinations. Associations between the sum
scores of BM or PD of the comprehensive joint score
and the different reduced joint combinations (described
in Table 1) were assessed by use of Spearman’s rank
correlations. A P-value < 0.05 was considered statisti-
cally significant. Responsiveness was visualized by use of
simple error bar plots with 95% confidence interval.
Results
PIP3, MCP 1 and 2, CMC1, radiocarpal- and radioulnar
joints, MTP 1, 2, 3 and 5 were inflamed (BM ≥ 1) at
one or both sides in ≥ 50% of the patients at baseline.
High BM scores (2 or 3) were found in MCP 1 and 2,
CMC1, radiocarpal- and radioulnar joints, MTP 1, 2 and
3 at one or both sides in ≥ 40% of the patients and high
PD activity (score 2 or 3) was detected in MCP 1, 2 and
Table 1 The joints, tendons and bursae included in the 7-
, 12-, 28- and 44-joint scores
Reduced joint
score
Joints, tendons and bursae included
7-joint score [9] On the clinically dominant side:
Wrist, MCP 2 and 3, PIP 2 and 3, MTP 2 and 5
Dorsal, ulnar and palmar tendon sheaths of the wrist,
flexor tendon sheaths of 2 and 3 finger,
paratendonitis dorsal 2 and 3 finger
12-joint score
[10]
Bilateral examination of:
Elbow, wrist, MCP 2 and 3, knee and ankle
Medial and lateral tendon sheaths of the ankle
28-joint score
[12]
Bilateral examination of:
Shoulder (glenohumeral), elbow, wrist, MCP 1 to 5, PIP
1 to 5 and knee
44-joint score
[10]
Bilateral examination of:
Shoulder (glenohumeral), elbow, wrist, MCP 1 to 5, PIP
1 to 5, hip, knee, ankle, mid-tarsal, MTP 1 to 5
Biceps tendon sheath, extensor and flexor tendons
sheaths of the wrist, flexor tendons sheaths of the
fingers, anterior, medial and lateral tendon sheaths of
the ankle
Subdeltoid bursa
MCP, metacarpo-phalangeal joint; PIP, proximal inter-phalangeal joint; MTP,
metatarso-phalangeal joint
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5, CMC1, radiocarpal- and radioulnar joints, MTP 2 and
5 at one or both sides in at least 30% of the patients.
Thus, all the different joint combinations include most
of the joints which were found to be frequently
inflamed.
High correlations were found between the sum BM
78-joint score and all of the different joint combinations,
with median (range) correlation coefficients at the five
examinations of 0.89 (0.86 to 0.96) for BM 7-joint score,
0.86 (0.79 to 0.96) for BM 12-joint score, 0.95 (0.92 to
0.97) for BM 28-joint score and 0.97 (0.95 to 0.99) for
BM 44-joint score (each P < 0.001). High correlations
were also found between the sum PD 78-joint score and
all of the joint combinations with median (range) 0.85
(0.80 to 0.95) for PD 7-joint score, 0.81 (0.77 to 0.90)
for PD 12-joint score, 0.93 (0.89 to 0.95) for PD 28-joint
score and 0.98 (0.95 to 0.99) for PD 44-joint score (each
P < 0.001). Tables 2 and 3 show the correlation coeffi-
cients between all the joint combinations at baseline
and at the 12-month follow-up.
All the joint combinations showed significant
improvement in sum scores of BM and PD during treat-
ment (Tables 4 and 5), which is illustrated by use of
error bar plots of the sum BM or PD scores at all exam-
inations (Figure 1). In particular, the more comprehen-
sive joint counts did not seem to have superior
responsiveness compared to the counts with inclusion of
fewer joints/tendons.
Discussion
To our knowledge the present longitudinal study with
examinations of a large number of joints, tendons and
bursae is the most comprehensive US assessment pub-
lished so far. During biological treatment the US scores
based on a reduced number of joints and tendons were
found to have high correlations with the comprehensive
score at all examinations and to provide comparable
information to the comprehensive score regarding
responsiveness. In addition, we found that the most
frequently inflamed joints with high degrees of BM and
PD pathology were included in the described reduced
joint counts. The CMC 1 joint, however, is often
involved in osteoarthritis [21,22] and this joint may not
be useful for evaluation of RA activity. This joint is also
not considered in the new ACR/EULAR classification
criteria for RA [23].
The present US assessments of joints and tendons
were slightly different from some of the reduced joint
scores. The most important difference was the scanning
method of MCP and PIP joints, where the 7-joint score
assesses both the palmar and dorsal side, while only
dorsal assessments were performed in the 78-joint score.
There is so far no consensus on which side of these fin-
ger joints US examinations give the most sensitive and/
or reliable results, but up to now the majority of studies
have assessed the dorsal part of the finger joints.
The PD scores in the 78-joint examination were
defined as none, minor, moderate or major presence of
PD activity. The PD scoring in the reduced joint scores
were slightly different and performed as described by
Szkudlarek et al. [24,25] who define score 2 or 3 as a
PD signal covering less or more than 50% of the synovi-
tis area. However, it may be difficult to differentiate
between these scores since most machines do not have
programs defining a certain percentage of PD activity
relative to grey scale pathology.
The various scores that are explored in this study have
been evaluated in longitudinal studies and are found to
detect improvement during biological medication. So
far, most evaluations of response to treatment have been
performed by use of the patient’s evaluations, clinical
examinations and laboratory assessments, and with pre-
sentation of composite scores that reflect inflammatory
activity [12,26-28], in accordance with the published
EULAR/ACR recommendations [29]. US has in previous
studies been found to be a valid and reliable examina-
tion for assessment of synovitis as well as the degree of
vascularization (by use of PD activity) [2-5]. Since the
Table 2 Correlation coefficients between sum scores B-
mode (BM) of the different joint combinations
BM 12-joint
score
BM 28-joint
score
BM 44-joint
score
BM 78-joint
score
BM 7-joint
score
0.87/0.92 0.86/0.89 0.85/0.91 0.87/0.93
BM 12-joint
score
0.84/0.93 0.86/0.96 0.87/0.96
BM 28-joint
score
0.94/0.93 0.95/0.93
BM 44-joint
score
0.97/0.99
Spearman’s rank correlation coefficients between sum scores BM of the
different joint combinations at baseline and at 12 months follow-up (in bold
italics) (P < 0.001 for all the correlations).
Table 3 Correlation coefficients between sum scores
power Doppler (PD) of the different joint combinations
PD 12-joint
score
PD 28-joint
score
PD 44-joint
score
PD 78-joint
score
PD 7-joint
score
0.89/0.89 0.92/0.94 0.94/0.93 0.95/0.95
PD 12-joint
score
0.81/0.85 0.86/0.85 0.86/0.89
PD 28-joint
score
0.94/0.95 0.93/0.95
PD 44-joint
score
0.95/0.98
Spearman’s rank correlation coefficients between sum scores PD of the
different joint combinations at baseline and at 12 months follow-up (in bold
italics) (P < 0.001 for all the correlations).
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primary goal for RA management is to suppress the
inflammation to a level that prevents disability and joint
destruction [30], US may be an additional promising
clinical tool for evaluation of response to treatment and
level of inflammatory activity. However, to make US a
feasible method in the clinical setting, it is of major
importance to explore the lowest number of joints and
tendons that is able to give information about the
inflammatory process in most of the patients. The pre-
sent study indicates that assessment of as few as seven
joints and five tendons/tendon compartments is sensi-
tive to change and with high correlations to the compre-
hensive joint and tendon assessment. The inclusion of a
few tendons is supported by a recent study where the
extensor carpi ulnaris and tibialis posterior tendons
were found to be most frequently inflamed and with US
scoring of these tendons being highly sensitive to
improvement during treatment [15]. Thus further stu-
dies ought to be performed to identify the joints and
tendons that should be included in a limited US score.
In a study of RA patients in clinical as well as ACR
and DAS28 remission, the majority of patients had US
evidence of inflammation when eight joints were
assessed (dominant hand MCP 2 to 5 and four wrist
joints) [31]. Thus, this low number of joints was able to
detect ongoing pathology in spite of normal combined
clinical and laboratory composite scores. In the search
for an optimal combination of joints and tendons for
US scoring of RA patients, this scoring system should
also be explored for its sensitivity to evaluate US remis-
sion in RA patients.
The strength of the present study is the performance
of a comprehensive joint, tendon and bursae assess-
ment by only one experienced sonographer in a longi-
tudinal design during anti-TNF treatment, use of
standardized US assessments utilizing the same
machine throughout the study and no missing exami-
nations. However, an obvious weakness is the low
number of participating patients. For this reason we
were not able to use the dataset to identify a new US
joint combination with high trade-off between feasibil-
ity and responsiveness. Nevertheless, in spite of the
low number of patients included, the present study
was able to detect significant associations between the
different joint scores as well as significant improve-
ments in all the US scores.
Conclusions
The joints found to be most frequently inflamed in the
present study are to a large extent included in the dif-
ferent described reduced joint combinations. All the
reduced joint scores were found to have high associa-
tions to the comprehensive 78-joint score and they
were sensitive to change during biological medication.
Even the 7-joint score was as sensitive to change as
the 78-joint score for BM and PD assessments. The
optimal combination of joints and tendons to be
assessed by US should be further explored to make a
valid, reliable and feasible score. However, the present
study supports that even low numbers of joints and
tendons seem to be sufficient to reflect the response to
biological treatment.
Table 4 Sum B-mode (BM) scores of the different joint combinations during the study
Baseline 1 month 3 months 6 monhts 12 months
7-joint score 11.5 (1 to 22) 7.5 (0 to 20)* 6.5 (0 to 15)* 7.0 (0 to 17)** 5.5 (0 to 16)**
12-joint score 15.0 (0 to 52) 12.5 (0 to 37)* 11.0 (0 to 28)* 9.5 (0 to 32)* 7.5 (0 to 28)*
28-joint score 17.0 (2 to 65) 13.0 (2 to 57)** 11.0 (0 to 45)** 8.5 (1 to 45)* 12.0 (0 to 45)*
44-joint score 40.0 (6 to 131) 31.5 (3 to 103)** 29.5 (6 to 71)** 19.5 (1 to 69)** 20.0 (1 to 73)**
78-joint score 53.5 (6 to 154) 38.5 (3 to 124)** 36.5 (6 to 96)** 23.5 (1 to 91)** 27.0 (1 to 101)**
Sum BM scores of the different joint combinations at baseline and after 1, 3, 6 and 12 months. All joint combinations showed significant change from baseline (*
= P ≤ 0.05, ** = P ≤ 0.001).
Table 5 Sum power Doppler (PD) scores of the different joint combinations during the study
Baseline 1 month 3 months 6 monhts 12 months
7-joint score 8.0 (0 to 19) 5.0 (0 to 17)* 3.5 (0 to 13)* 2.0 (0 to 12)** 2.5 (0 to 12)**
12-joint score 9.0 (0 to 42) 8.0 (0 to 31) 6.5 (0 to 26)** 6.0 (0 to 29)* 3.0 (0 to 29)*
28-joint score 10.5 (0 to 50) 8.0 (0 to 34)* 3.5 (0 to 28)** 3.5 (0 to 35)** 4.0 (0 to 35)*
44-joint score 26.5 (1 to 96) 17.0 (0 to 63)** 11.5 (1 to 38)** 12.0 (0 to 63)** 9.5 (0 to 73)**
78-joint score 33.0 (1 to 119) 21.0 (0 to 83)** 15.5 (2 to 52)** 13.5 (0 to 82)** 12.5 (0 to 81)**
Sum PD scores of the different joint combinations at baseline and after 1, 3, 6 and 12 months. All joint combinations showed significant change from baseline (*
= P ≤ 0.05, ** = P ≤ 0.001).
Hammer and Kvien Arthritis Research & Therapy 2011, 13:R78
http://arthritis-research.com/content/13/3/R78
Page 5 of 8
                    
         
         
7-joint score; BM and PD 
12-joint score; BM and PD 
28-joint score; BM and PD 
44-joint score; BM and PD 
78-joint score; BM and PD
Figure 1 Error bar chart of the 7-, 12-, 28-, 44- and 78 joint scores for the mean sum BM or PD scores (with 95% confidence interval).
BM; B-mode, PD; power Doppler
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